Skip to search formSkip to main contentSkip to account menu

BXL628

Known as: BXL-628 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Calcitriol

Narrower (1)

Elocalcitol
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ROCK pathway in HK-2 cells.
It has previously been reported that 1,25-(OH)2D3 inhibits high glucose-induced epithelial-to-mesenchymal transition (EMT) in HK… 
Highly Cited
2007
Highly Cited
2007
BXL‐628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder
BXL‐628 is a calcitriol analog shown to decrease prostate growth in preclinical and clinical studies. BPH symptoms are generated… 
2006
2006
The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells
Purpose: Suppression of the invasive phenotype is essential in developing new therapeutic tools to treat advanced prostate cancer… 
2006
2006
Effects of a vitamin D3 analogue in a rat model of bladder outlet obstruction
To explore the effect of the vitamin D3 analogue, BXL‐628, on some of the consequences of bladder outlet obstruction (BOO), e.g… 
2006
2006
Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction.
OBJECTIVES To explore the effect of the vitamin D3 analogue, BXL-628, on some of the consequences of bladder outlet obstruction… 
Review
2006
Review
2006
Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)
The active form of vitamin D, 1,25-dihydroxyvitamin D3, is a secosteroid hormone that binds to the vitamin D receptor (VDR), a… 
Highly Cited
2006
Highly Cited
2006
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
2006
2006
Oral treatment with a vitamin D3 analogue (BXL628) has anti‐inflammatory effects in rodent model of interstitial cystitis
To investigate the effects of a vitamin D3 analogue (BXL628) in a model of chronic cystitis, as calcitriol analogues might be an… 
2006
2006
The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.
Medical therapy is the preferred first-line approach in the management of lower urinary tract symptoms in men with benign… 
2005
2005
Inhibition of Acute and Chronic Allograft Rejection in Mouse Models by BXL-628, a Nonhypercalcemic Vitamin D Receptor Agonist
Background. Vitamin D receptor (VDR) agonists are immunomodulatory agents that have been shown to prolong allograft survival in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)